Glenmark Lifesciences' PAT dips 5.5% yoy for Q4FY22; revenue grows 10% yoy

21 Apr 2022 , 09:10 AM

Glenmark Lifesciences Limited has reported its results for the quarter and financial year ended March 2022. The company witnessed strong growth momentum in the year across key regulated markets.

Revenue grew at 10% yoy in Q4 and 12.6% in FY22. Revenue for Q4FY22 was Rs514.06 crore as against Rs4,671.60 in Q4FY21. While revenue for the financial year ended March 2022 was reported at Rs2,123.21 crore as compared to Rs1,885.17 crore for FY22.

EBITDA for Q4FY22 dipped 13.5% yoy at Rs147.31 crore as compared to Rs170.23 crore for Q4FY21. For the financial year 2021-22, EBIDTA gained 6.6% yoy at Rs630.76 crore against Rs591.88 crore in FY21.

EBITDA margin for the financial year and quarter ended March 2022 was 28.7% and 29.7% respectively.

Company’s PAT for Q4FY22 was Rs98.90 crore as compared to Rs104.68 crore in Q4FY21, reporting a decline of 5.5% yoy.

PAT for the financial year ended March 2022 jumped 19.1% yoy at Rs418.72 crore as compared to Rs351.58 crore in FY21.

Net Profits Margin for Q4FY22 and FY22 were 19.2% and 19.7% respectively, improved due to debt repayments made by the company.

The company incurred R&D expenditure at 2.8% during the quarter and 2.7% for FY22.

For FY22, Capital expenditures incurred were Rs145.10 crore. Company’s ROCE is tracking at 29% for FY22.

At around 9.20 AM, Glenmark Life Sciences was trading at Rs488.65 down by Rs0.45 or 0.09% from its previous closing of Rs489.10 on the BSE.